The DOI matches its Crossref record; 387 of the 389 references it cites were found in a registry or an index.
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases
Open accessAbstract
An estimated 20-25% of the population is affected by chronic, non-communicable inflammatory skin diseases. Chronic skin inflammation has many causes. Among the most frequent chronic inflammatory skin diseases are atopic dermatitis, psoriasis, urticaria, lichen planus, and hidradenitis suppurativa, driven by a complex interplay of genetics and environmental factors. Autoimmunity is another important cause of chronic skin inflammation. The autoimmune response may be mainly T cell driven, such as in alopecia areata or vitiligo, or B cell driven in chronic spontaneous urticaria, pemphigus and pemphigoid diseases. Rare causes of chronic skin inflammation are autoinflammatory diseases, or rheumatic diseases, such as cutaneous lupus erythematosus or dermatomyositis. Whilst we have seen a significant improvement in diagnosis and treatment, several challenges remain. Especially for rarer causes of chronic skin inflammation, early diagnosis is often missed because of low awareness and lack of diagnostics. Systemic immunosuppression is the treatment of choice for almost all of these diseases. Adverse events due to immunosuppression, insufficient therapeutic responses and relapses remain a challenge. For atopic dermatitis and psoriasis, a broad spectrum of innovative treatments has been developed. However, treatment responses cannot be predicted so far. Hence, development of (bio)markers allowing selection of specific medications for individual patients is needed. Given the encouraging developments during the past years, we envision that many of these challenges in the diagnosis and treatment of chronic inflammatory skin diseases will be thoroughly addressed in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–387 of 387
De, D., Kanwar, A., & Handa, S. (2006) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2006.01664.x · Cited by 85 · cited 1×
“There are diagnostic criteria, but no simple test for definitive diagnosis (49).”
BackgroundFcR-Independent Effects of IgE and IgG Autoantibodies in Bullous Pemphigoid
Messingham, K. N., Srikantha, R., DeGueme, A. M., & Fairley, J. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1001753 · Cited by 85
Immune response in pemphigus and beyond: progresses and emerging concepts
Zenzo, G. D., Amber, K. T., Sayar, B. S., Müller, E. J., & Borradori, L. (2015) · Seminars in Immunopathology · doi:10.1007/s00281-015-0541-1 · Cited by 85
Nail changes in alopecia areata: an update and review
Chelidze, K., & Lipner, S. R. (2018) · International Journal of Dermatology · doi:10.1111/ijd.13866 · Cited by 85
Targeted Therapies for Autoimmune Bullous Diseases: Current Status
Amber, K. T., Maglie, R., Solimani, F., Eming, R., & Hertl, M. (2018) · Drugs · doi:10.1007/s40265-018-0976-5 · Cited by 85
Peripheral Sensitization and Loss of Descending Inhibition Is a Hallmark of Chronic Pruritus
Pogatzki-Zahn, E. M., Pereira, M. P., Cremer, A. F., Zeidler, C., Dreyer, T., Riepe, C., Wempe, C., Lotts, T., Segelcke, D., Ringkamp, M., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2019.05.029 · Cited by 85 · cited 1×
“Recent studies suggested that nerve fiber dysfunction and structural neuroanatomical changes are present in PN skin which are induced by scratching and maintained by inflammation (96, 97).”
BackgroundSchmidt, T., Solimani, F., Pollmann, R., Stein, R., Schmidt, A., Stulberg, I., Kühn, K., Eming, R., Eubel, V., Kind, P., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.044 · Cited by 85 · cited 2×
“This offlabel use of these therapeutics was based on the observation of a Th1/Th17-dominated cell response in the peripheral blood of LP patients (1).”
BackgroundAdult-Onset Atopic Dermatitis: Characteristics and Management
Vakharia, P. P., & Silverberg, J. I. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-019-00453-7 · Cited by 84
Treatment of severe lichen planus with the JAK inhibitor tofacitinib
Damsky, W., Wang, A., Olamiju, B., Peterson, D. M., Galan, A., & King, B. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.01.031 · Cited by 84 · cited 2×
“, tofacitinib) have been shown to be effective (109, 117).”
BackgroundDidona, D., Fania, L., Didona, B., Eming, R., Hertl, M., & Zenzo, G. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062178 · Cited by 84 · cited 1×
“host disease, granuloma annulare, oral candidiasis, and oral leukoplakia (113).”
BackgroundNast, A., Altenburg, A., Augustin, M., Boehncke, W., Härle, P., Klaus, J., Koza, J., Mrowietz, U., Ockenfels, H. M., Philipp, S., et al. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14508 · Cited by 84
AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome
Wechalekar, A. D., Lachmann, H. J., Goodman, H. J. B., Bradwell, A. R., Hawkins, P. N., & Gillmore, J. D. (2008) · Blood · doi:10.1182/blood-2008-02-138156 · Cited by 83
Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis
Greiner, G., Gurbisz, M., Ratzinger, F., Witzeneder, N., Simonitsch-Klupp, I., Mitterbauer-Hohendanner, G., Mayerhofer, M., Müllauer, L., Sperr, W. R., Valent, P., et al. (2018) · Clinical Chemistry · doi:10.1373/clinchem.2017.277897 · Cited by 83
Das, D., Akhtar, S., Kurra, S., Gupta, S., & Sharma, A. (2019) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2019.01.001 · Cited by 83 · cited 1×
“The ultimate goal must be to find and apply the most effective, and at the same time best tolerated therapy for each individual patient at any point in their “disease career,” sometimes in a quite variable manner (87).”
BackgroundArmstrong, A. W., Soliman, A. M., Betts, K. A., Wang, Y., Gao, Y., Puig, L., & Augustin, M. (2021) · Dermatology and Therapy · doi:10.1007/s13555-021-00511-1 · Cited by 83
Autoantibody Markers of Increased Risk of Malignancy in Patients with Dermatomyositis
Marzęcka, M., Niemczyk, A., & Rudnicka, L. (2022) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-022-08922-4 · Cited by 83
Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis
Ständer, S., Ketz, M., Kossack, N., Akumo, D., Pignot, M., Gabriel, S., & Chavda, R. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3655 · Cited by 82
Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis
Williams, K. A., Roh, Y. S., Brown, I. D., Sutaria, N. H., Bakhshi, P. R., Choi, J., Gabriel, S., Chavda, R., & Kwatra, S. G. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1852080 · Cited by 81 · cited 1×
“Currently, neuroimmune mechanisms are considered the dominant mechanism underlying PN (93).”
BackgroundThalidomide and its impact in dermatology
Stirling, D. (1998) · Seminars in Cutaneous Medicine and Surgery · doi:10.1016/s1085-5629(98)80019-9 · Cited by 80
Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)
Ujiie, H., Iwata, H., Yamagami, J., Nakama, T., Aoyama, Y., Ikeda, S., Ishii, N., Iwatsuki, K., Kurosawa, M., Sawamura, D., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15111 · Cited by 80
Updates and new medical treatments for vitiligo (Review)
Kubelis‐López, D. E., Zapata‐Salazar, N. A., Said‐Fernández, S., Sanchez-Dominguez, C. N., Salinas-Santander, M. A., Martı́nez-Rodrı́guez, H. G., Vázquez‐Martínez, O., Wollina, U., Lotti, T., & Ocampo‐Candiani, J. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10229 · Cited by 80
Emerging drugs for the treatment of vitiligo
Karagaiah, P., Valle, Y., Sigova, J., Zerbinati, N., Vojvodić, P., Parsad, D., Schwartz, R. A., Grabbe, S., Goldust, M., & Lotti, T. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1712358 · Cited by 78 · cited 2×
“Thus, the future of vitiligo treatment may rely on the development of more specific drugs (167).”
BackgroundConti, P., Pregliasco, F. E., Bellomo, R. G., Gallenga, C. E., Caraffa, A., Kritas, S. K., Lauritano, D., & Ronconi, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158076 · Cited by 78
ISLAM, M. N., HOSSAIN, M., Haq, S. A., Alam, M. N. A., ten Klooster, P. M., & Rasker, J. J. (2011) · International Journal of Rheumatic Diseases · doi:10.1111/j.1756-185x.2011.01665.x · Cited by 76
Arai, M., Shirakawa, J., Konishi, H., Sagawa, N., & Terauchi, Y. (2018) · Diabetes Care · doi:10.2337/dc18-0210 · Cited by 76
Foster, C. S. (1986) · PubMed · Cited by 75
Park, E. H., Strand, V., Oh, Y. J., Song, Y. W., & Lee, E. B. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1842-x · Cited by 74
Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease
Iznardo, H., & Puig, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094344 · Cited by 74 · cited 1×
“A good example of this is the development of IL-36 antagonists or blockade of other members of the IL-1 family (83), which are proving to be promising in pustular and highly inflammatory forms of psoriasis (84).”
BackgroundGoletz, S., Probst, C., Komorowski, L., Schlumberger, W., Fechner, K., van Beek, N., Holtsche, M. M., Recke, A., Yancey, K. B., Hashimoto, T., et al. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17202 · Cited by 73
Race-Specific Prevalence of Hidradenitis Suppurativa
Sachdeva, M., Shah, M., & Alavi, A. (2020) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475420972348 · Cited by 73
Individualizing treatment and choice of medication in lichen planus: a step by step approach
Manousaridis, I., Manousaridis, K., Peitsch, W. K., & Schneider, S. W. (2013) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.12141 · Cited by 72
Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease
Patel, B., Khan, N., & Werth, V. P. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.055 · Cited by 72
Current Clinical Trials in Pemphigus and Pemphigoid
Izumi, K., Bieber, K., & Ludwig, R. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00978 · Cited by 72
Prednisone therapy for alopecia areata. A follow-up report
Winter, R. J. (1976) · Archives of Dermatology · doi:10.1001/archderm.112.11.1549 · Cited by 72
Efficacy of mycophenolate mofetil in antimalarial-resistant cutaneous lupus erythematosus
Gammon, B., Hansen, C., & Costner, M. I. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.08.011 · Cited by 71
Khan, S. J., Dharmage, S. C., Matheson, M. C., & Gurrin, L. C. (2017) · Allergy · doi:10.1111/all.13228 · Cited by 70 · cited 1×
“Both genetics and environmental factors play a role in the pathogenesis (42).”
BackgroundFeatures Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients
Schneider‐Burrus, S., Tsaousi, A., Barbus, S., Huss‐Marp, J., Witte, K., Wolk, K., Fritz, B., & Sabat, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.676241 · Cited by 69 · cited 1×
“However, surgical and conventional pharmacologic therapies of HS are not associated with long-lasting improvement of patients’ quality of life (132).”
BackgroundRole of Janus Kinase Inhibitors in Therapy of Psoriasis
Słuczanowska-Głąbowska, S., Ziegler-Krawczyk, A., Szumilas, K., & Pawlik, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194307 · Cited by 69 · cited 1×
“The background for the latter development is the recognition that many mediators, for example type I interferons or IL-23, mediate their inflammatory signals via Janus kinases (JAK, to which TYK2 also belongs) (85, 86).”
BackgroundAssociation of Hidradenitis Suppurativa With Body Image
Schneider‐Burrus, S., Jost, A., Peters, E. M. J., Witte-Haendel, E., Sterry, W., & Sabat, R. (2018) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.6058 · Cited by 68
Petersen, M. P., Möller, S., Bygum, A., Voss, A., & Bliddal, M. (2018) · Lupus · doi:10.1177/0961203318777103 · Cited by 68
Autoantibody-Specific Signalling in Pemphigus
Schmitt, T., & Waschke, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.701809 · Cited by 68
Meijer, J. M., Atefi, I., Diercks, G. F. H., Vorobyev, A., Zuiderveen, J., Meijer, H. J., Pas, H. H., Zillikens, D., Schmidt, E., & Jonkman, M. F. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.11.029 · Cited by 67
Balakirski, G., Alkhateeb, A., Merk, H. F., Leverkus, M., & Megahed, M. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13758 · Cited by 66
Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus
Kushner, C. J., Wang, S., Tovanabutra, N., Tsai, D. E., Werth, V. P., & Payne, A. S. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3236 · Cited by 66
Photodynamic therapy in oral lichen planus: A prospective case-controlled pilot study
Cosgarea, R., Pollmann, R., Sharif, J., Schmidt, T., Stein, R., Bodea, A., Auschill, T. M., Sculean, A., Eming, R., Greene, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58548-9 · Cited by 66
Fetter, T., Smith, P. A., Guel, T., Braegelmann, C., Bieber, T. R. M., & Wenzel, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00344 · Cited by 66
Wolk, K., Brembach, T.-C., Šimaitė, D., Bartnik, E., Cucinotta, S., Pokrywka, A., Irmer, M. L., Triebus, J., Witte‐Händel, E., Salinas, G., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19795 · Cited by 66
Cutaneous Dermatomyositis: An Updated Review of Treatment Options and Internal Associations
Femia, A. N., Vleugels, R. A., & Callen, J. P. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0028-6 · Cited by 64
Heppe, E. N., Tofern, S., Schulze, F. S., Ishiko, A., Shimizu, A., Sina, C., Zillikens, D., Köhl, J., Goletz, S., & Schmidt, E. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.03.037 · Cited by 64
Concha, J. S. S., Tarazi, M., Kushner, C. J., Gaffney, R. G., & Werth, V. P. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17536 · Cited by 64
Bellando-Randone, S., & Matucci‐Cerinic, M. (2019) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2019.101428 · Cited by 64
Mechanisms of skin autoimmunity: Cellular and soluble immune components of the skin
Gudjonsson, J. E., Kabashima, K., & Eyerich, K. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.05.009 · Cited by 64 · cited 1×
“The categorization and characterization of inflammatory and autoimmunity patterns, which is already under development, may help in this regard (77).”
BackgroundTerra, J. B., Pas, H. H., Hertl, M., Dikkers, F. G., Smitt-Kamminga, N. S., & Jonkman, M. F. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10474.x · Cited by 63
Investigator’s Global Assessment of Chronic Prurigo: A New Instrument for Use in Clinical Trials
Zeidler, C., Pereira, M. P., Augustin, M., Spellman, M. C., & Ständer, S. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3701 · Cited by 63
Severity, heterogeneity and systemic inflammation in psoriasis
Christophers, E., & van de Kerkhof, P. C. M. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15339 · Cited by 61 · cited 1×
“Furthermore, as detailed below, for many chronic skin inflammatory diseases the clinical presentation varies greatly even within the same disease, as with psoriasis or bullous pemphigoid (3, 4).”
BackgroundPenno, C. A., Jäger, P., Laguerre, C., Hasler, F., Hofmann, A., Gass, S. K., Wettstein-Ling, B., Schaefer, D. J., Avraméas, A., Raulf, F., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.04.011 · Cited by 61
van Leeuwen, N. M., Ciaffi, J., Liem, S. I. E., Huizinga, T. W. J., & Vries-Bouwstra, J. K. D. (2020) · Lara D. Veeken · doi:10.1093/rheumatology/keaa827 · Cited by 61
High Prevalence of Back Pain and Axial Spondyloarthropathy in Patients with Hidradenitis Suppurativa
Schneider‐Burrus, S., Witte-Haendel, E., Christou, D., Rigoni, B., Sabat, R., & Diederichs, G. (2016) · Dermatology · doi:10.1159/000448838 · Cited by 60
Kim, J. H., Kim, Y. H., Kim, S. I., Noh, E. B., Kim, S., Vorobyev, A., Schmidt, E., Zillikens, D., & Kim, S. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2012.04617.x · Cited by 59
Intralesional steroids for alopecia areata
Kumaresan, M. (2010) · International Journal of Trichology · doi:10.4103/0974-7753.66920 · Cited by 59 · cited 1×
“The first line of therapy in AAP patients with active disease include intralesional (triamcinolone acetonide, triamcinolone hexacetonide, and hydrocortisone acetate) and topical corticosteroids (desoximetasone, betamethasone valerate, and clobetasol propionate), which show low solubility and promote maximum local anti…”
BackgroundLangenbruch, A. K., Radtke, M. A., Franzke, N., Ring, J., Foelster‐Holst, R., & Augustin, M. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12154 · Cited by 59 · cited 1×
“There can be a significant effect on patient’s quality of life and sleep due to itch and pain (37).”
BackgroundHistopathology of alopecia areata, acute and chronic: Why is it important to the clinician?
Dy, L. C., & Whiting, D. A. (2011) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2011.01414.x · Cited by 59 · cited 2×
“Other histological signs of AA characteristic of acute and the subacute phases include hair follicle miniaturization, a decreased anagen-to-telogen ratio, and a decreased terminal-to-vellus hair ratio (148).”
Backgroundvan Beek, N., Weidinger, A.-K., Schneider, S., Kleinheinz, A., Gläser, R., Holtsche, M. M., von Georg, A., Hammers, C. M., Hübner, F., Lima, A. L., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17107 · Cited by 59
Patients’ views and needs about systemic sclerosis and its management: a qualitative interview study
Mouthon, L., Alami, S., Boisard, A.-S., Chaigne, B., HACHULLA, E., & Poiraudeau, S. (2017) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-017-1603-4 · Cited by 58
Schnitzler syndrome: an under-diagnosed clinical entity
Jain, T., Offord, C. P., Kyle, R. A., & Dingli, D. (2013) · Haematologica · doi:10.3324/haematol.2013.084830 · Cited by 57
Racial characteristics of alopecia areata in the United States
Lee, H., Jung, S. J., Patel, A. B., Thompson, J. M., Qureshi, A. A., & Cho, E. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.06.1300 · Cited by 57
Shimanovich, I., Nitz, J. M., & Zillikens, D. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.05.016 · Cited by 56
Cross‐European validation of the ItchyQoL in pruritic dermatoses
Zeidler, C., Steinke, S., Riepe, C., Bruland, P., Soto‐Rey, I., Storck, M., Garcovich, S., Blome, C., Bobko, S., Legat, F. J., et al. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15225 · Cited by 55 · cited 1×
“The health-related quality of life can be documented either by Dermatology Life Quality Index (DLQI) or the itch-specific ItchyQol (102).”
BackgroundCROWSON, A. N., MAGRO, C. M. J., & Mihm, M. C. (2008) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2008-132-652-id · Cited by 54
Bellinato, F., Gisondi, P., & Girolomoni, G. (2021) · Biologics · doi:10.2147/btt.s290309 · Cited by 53 · cited 2×
“Very recent developments also include mirikizumab and netakimab (73).”
BackgroundCutaneous involvement of dermatomyositis can respond to Dapsone therapy
Cohen, J. B. (2002) · International Journal of Dermatology · doi:10.1046/j.1365-4362.2002.01409.x · Cited by 52
Shiel, W. C., & Jason, M. (1989) · PubMed · Cited by 52
S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 1
Eisert, L., Augustin, M., Bach, S., Dittmann, M., Eiler, R., Fölster‐Holst, R., Gerdes, S., Hamm, H., Hoeger, P. H., Horneff, G., et al. (2019) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13907 · Cited by 52 · cited 1×
“These therapies have been and continue to be included in current guidelines (67, 68, 74, 75).”
BackgroundThe Diagnostic Workup in Chronic Spontaneous Urticaria—What to Test and Why
Metz, M., Altrichter, S., Buttgereit, T., Fluhr, J. W., Fok, J. S., Hawro, T., Jiao, Q., Kolkhir, P., Krause, K., Magerl, M. A. K., et al. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.03.049 · Cited by 52
Contact urticaria during topical immunotherapy
Tosti, A., Guerra, L., & Bardazzi, F. (1989) · Contact Dermatitis · doi:10.1111/j.1600-0536.1989.tb04737.x · Cited by 51 · cited 1×
“Several side effects associated with this treatment include severe contact dermatitis, occipital or cervical lymphadenopathy, urticaria, dyschromia, and vitiligo (156, 157).”
BackgroundCytokines of the IL‐17 family in psoriasis
Lauffer, F., Eyerich, K., Boehncke, W., Asadullah, K., Beissert, S., Ghoreschi, K., & Schön, M. P. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14124 · Cited by 51 · cited 1×
“In addition, IL-17A and IL-17 F may also act as heterodimers at the receptor (82).”
BackgroundTherapeutic Development Based on the Immunopathogenic Mechanisms of Psoriasis
Tseng, J., Chang, Y.-C., Huang, C., Hsu, L.-C., & Chuang, T. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13071064 · Cited by 51 · cited 1×
“Several new drugs have been and are being developed first for psoriasis and then extended to other indications (61).”
BackgroundMai, Y., Nishie, W., Sato, K., Hotta, M., Izumi, K., Ito, K., Hosokawa, K., & Shimizu, H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00542 · Cited by 50
Magee, C., Jethwa, H., FitzGerald, O., & Jadon, D. R. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211014010 · Cited by 50
Augustin, M., Garbe, C., Hagenström, K., Petersen, J., Pereira, M. P., & Ständer, S. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17485 · Cited by 50
Prednisone Therapy for Alopecia Areata
Winter, R. J. (1976) · Archives of Dermatology · doi:10.1001/archderm.1976.01630350025006 · Cited by 50 · cited 1×
“However, one major drawback of this line of therapy includes recurrence of hair loss after therapy is discontinued (153).”
BackgroundTsaousi, A., Witte, E., Witte, K., Röwert‐Huber, H., Volk, H., Sterry, W., Wolk, K., Schneider‐Burrus, S., & Sabat, R. (2016) · Mediators of Inflammation · doi:10.1155/2016/4097574 · Cited by 49
Pölking, J., Zeidler, C., Schedel, F., Osada, N., Augustin, M., Metze, D., Pereira, M. P., Yosipovitch, G., Bernhard, J. D., & Ständer, S. (2018) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15040 · Cited by 49 · cited 1×
“The validated investigator questionnaire Prurigo Activity and Severity Score (PAS) assesses several parameters of the disease such as type, number, and distribution of pruriginous lesions, proportion of PN lesions with excoriations and proportion of healed lesions (100).”
MethodAliaga, J., Bonaventura, A., Mezzaroma, E., Dhakal, Y., Mauro, A. G., Abbate, A., & Toldo, S. A. (2021) · Molecules · doi:10.3390/molecules26123534 · Cited by 49
Pereira, M. P., Pogatzki-Zahn, E. M., Snels, C., Vu, T., Üçeyler, N., Loser, K., Sommer, C., Evers, A. W. M., van Laarhoven, A. I. M., Agelopoulos, K., et al. (2017) · Experimental Dermatology · doi:10.1111/exd.13343 · Cited by 48 · cited 1×
“Recent studies suggested that nerve fiber dysfunction and structural neuroanatomical changes are present in PN skin which are induced by scratching and maintained by inflammation (96, 97).”
BackgroundSezin, T., Murthy, S., Attah, C., Seutter, M., Holtsche, M. M., Hammers, C. M., Schmidt, E., Meshrkey, F., Mousavi, S., Zillikens, D., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128239 · Cited by 48
Evaluation of Site- and Autoantigen-Specific Characteristics of Mucous Membrane Pemphigoid
van Beek, N., Kridin, K., Bühler, E., Kochan, A. S., Ständer, S., Ludwig, R. J., Zillikens, D., Schmidt, E., & Günther, C. (2021) · JAMA Dermatology · doi:10.1001/jamadermatol.2021.4773 · Cited by 48
Vitiligo complicating diphencyprone sensitization therapy for alopecia universalis
Henderson, C. A., & Ilchyshyn, A. (1995) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb02692.x · Cited by 47 · cited 1×
“Several side effects associated with this treatment include severe contact dermatitis, occipital or cervical lymphadenopathy, urticaria, dyschromia, and vitiligo (156, 157).”
BackgroundTiri, H., Jokelainen, J. J., Timonen, M., Tasanen, K., & Huilaja, L. (2018) · British Journal of Dermatology · doi:10.1111/bjd.17578 · Cited by 47
Current and emerging treatments for chronic spontaneous urticaria
Johal, K. J., & Saini, S. S. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.08.465 · Cited by 47
Hübner, F., König, I. R., Holtsche, M. M., Zillikens, D., Linder, R., & Schmidt, E. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16467 · Cited by 47
Bimekizumab for the Treatment of Psoriasis
Freitas, E., Blauvelt, A., & Torres, T. R. (2021) · Drugs · doi:10.1007/s40265-021-01612-z · Cited by 47 · cited 1×
“The most recently approved example is an antibody that blocks the effects of both IL-17A and IL-17F (bimekizumab) (81).”
BackgroundAsgari, M. M., Tsai, A., Avalos, L. A., Sokil, M., & Quesenberry, C. P. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.2240 · Cited by 46 · cited 1×
“While there was initial concern regarding the use of TCIs and the risk of malignancy, post-marketing research has been reassuring as to the safety of these treatments (58).”
BackgroundNast, A., Altenburg, A., Augustin, M., Boehncke, W., Härle, P., Klaus, J., Koza, J., Mrowietz, U., Ockenfels, H. M., Philipp, S., et al. (2021) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14507 · Cited by 46 · cited 2×
“These therapies have been and continue to be included in current guidelines (67, 68, 74, 75).”
BackgroundWei, W., Ghorayeb, E., Andria, M. L., Walker, V., Schnitzer, J., Kennedy, M., Chen, Z., Belland, A., White, J. C., & Silverberg, J. I. (2019) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2019.07.008 · Cited by 44 · cited 1×
“The high burden of disease can interfere with work productivity, not only from the baseline disease but particularly from flares (39).”
BackgroundKlebes, M., Wutte, N. J., & Aberer, E. (2015) · Dermatology · doi:10.1159/000441054 · Cited by 43
S2k guidelines for the treatment of psoriasis in children and adolescents – Short version part 2
Eisert, L., Augustin, M., Bach, S., Dittmann, M., Eiler, R., Fölster‐Holst, R., Gerdes, S., Hamm, H., Hoeger, P. H., Horneff, G., et al. (2019) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13936 · Cited by 42 · cited 1×
“These therapies have been and continue to be included in current guidelines (67, 68, 74, 75).”
BackgroundClinical presentation and diagnostic delay in pemphigus vulgaris: A prospective study from Turkey
Daltaban, Ö., Özçentik, A., Karakaş, A. A., Üstün, K., Hatipoğlu, M., & Uzun, S. (2020) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.13052 · Cited by 42
Aghamajidi, A., Raoufi, E., Parsamanesh, G., Jalili, A., Salehi‐Shadkami, M., Mehrali, M., & Mohsenzadegan, M. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.13000 · Cited by 41 · cited 1×
“On this basis, later extensions of indications are also conceivable for diseases that have similar pathogenetic features and for which, due to their relative rarity, large prospective clinical trials are usually not conducted (76).”
BackgroundMatsushima, S., Horiguchi, Y., Honda, T., Fujii, S., Okano, T., Tanabe, M., Wakayama, T., Hashimoto, T., & Yancey, K. B. (2004) · The Journal of Dermatology · doi:10.1111/j.1346-8138.2004.tb00497.x · Cited by 40
Dermatomyositis: A diagnostic dilemma
Silva, D. M. D., Patel, B., & Werth, V. P. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.12.074 · Cited by 40
Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid
Jafari, S. M. S., Gadaldi, K., Feldmeyer, L., Yawalkar, N., Borradori, L., & Schlapbach, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01919 · Cited by 40
Pereira, M. P., Zeidler, C., Wallengren, J., Halvorsen, J., Weißhaar, E., Garcovich, S., Misery, L., Brenaut, E., Şavk, E., Потекаев, Н. Н., et al. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3726 · Cited by 39 · cited 1×
“Novel, effective, safe and approved therapies are urgently needed as patients are in general dissatisfied with the currently medical care (103).”
Backgroundvan Beek, N., Zillikens, D., & Schmidt, E. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0136 · Cited by 39
Arora, S., Das, P. K., & Arora, G. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.696597 · Cited by 39 · cited 1×
“There is also not yet enough data on combination therapies for psoriasis (78).”
BackgroundDeveloping classification criteria for skin‐predominant dermatomyositis: the Delphi process
Concha, J. S. S., Pena, S. M., Gaffney, R. G., Patel, B., Tarazi, M., Kushner, C. J., Merola, J. F., Fiorentino, D. F., Dutz, J. P., Goodfield, M. J. D., et al. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18096 · Cited by 38
Vorobyev, A., Gupta, Y., Sezin, T., Koga, H., Bartsch, Y. C., Belheouane, M., Künzel, S., Sina, C., Schilf, P., Körber-Ahrens, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11952-w · Cited by 38
Ca 2+ signalling is critical for autoantibody‐induced blistering of human epidermis in pemphigus*
Schmitt, T., Egu, D. T., Walter, E., Sigmund, A. M., Eichkorn, R. A., Yazdi, A. S., Schmidt, E., Sárdy, M., Eming, R., Goebeler, M., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20091 · Cited by 38
Creation and Validation of Classification Criteria for Discoid Lupus Erythematosus
Elman, S. A., Joyce, C., Braudis, K., Chong, B. F., Fernandez, A. P., Furukawa, F., Hasegawa, M., Kim, H. J., Li, S. J., Lian, C. G., et al. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.1698 · Cited by 37
Li, L., Cui, Y., Chen, S., Zhao, Q., Fu, T., Ji, J., Li, L., & Gu, Z. (2018) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13438 · Cited by 36
Callen, J. P. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.04.007 · Cited by 35
Deza, G., March‐Rodríguez, Á., Sánchez, S., Ribas‐Llauradó, C., Soto, D., Pujol, R. M., Gimeno, R., & Giménez‐Arnau, A. M. (2019) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2019.01.026 · Cited by 35
Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment
Yuki, E. F. N., Silva, C. A., Aikawa, N. E., Romiti, R., Heise, C. O., Bonfá, E., & Pasoto, S. G. (2019) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001160 · Cited by 35
Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies.
Little, A. J., & Vesely, M. D. (2020) · PubMed · Cited by 35
Kimel, M., Zeidler, C., Kwon, P., Revicki, D. A., & Ständer, S. (2020) · JAMA Dermatology · doi:10.1001/jamadermatol.2020.3071 · Cited by 35
Unmet Patient Needs in Systemic Sclerosis
Rubenzik, T. T., & Derk, C. T. (2009) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31819dbe83 · Cited by 34
Biological therapies in the treatment of cutaneous lupus erythematosus
Presto, J. K., Hejazi, E. Z., & Werth, V. P. (2016) · Lupus · doi:10.1177/0961203316670731 · Cited by 34
Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis
Ständer, S., Augustin, M., Berger, T., Elmariah, S. B., Korman, N. J., Weißhaar, E., & Yosipovitch, G. (2020) · JAAD International · doi:10.1016/j.jdin.2020.10.009 · Cited by 34
Mehr, S. S., Allen, R. C., Boros, C. A., Adib, N., Kakakios, A. M., Turner, P., Rogers, M., Zurynski, Y. A., & Singh‐Grewal, D. (2016) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.13270 · Cited by 33
Hidradenitis suppurativa – prevalence analyses of German statutory health insurance data
Schneider‐Burrus, S., Lux, G., Linde, K., Barbus, S., Huss‐Marp, J., Tsaousi, A., Wasem, J., Wolff, B., & Sabat, R. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16783 · Cited by 33 · cited 2×
“HS leads to profound impairment in the quality of life of affected people, which is much more pronounced than the impairment caused by other dermatoses (16, 126).”
BackgroundDirect Immunofluorescence Using Non-Lesional Buccal Mucosa in Mucous Membrane Pemphigoid
Kamaguchi, M., Iwata, H., Ujiie, I., Ujiie, H., Sato, J., Kitagawa, Y., & Shimizu, H. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00020 · Cited by 32
Molecular Pathogenesis of Psoriasis and Biomarkers Reflecting Disease Activity
Honma, M., & Nozaki, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10153199 · Cited by 32 · cited 1×
“Hence, the establishment and clinical validation of biomarkers and molecular genetic patterns could enable predictions of response or loss of efficacy of specific therapies in individual patients (79).”
BackgroundMatusiak, Ł., Bieniek, A., & Szepietowski, J. C. (2009) · Biomarkers · doi:10.1080/13547500903075218 · Cited by 31
Lenalidomide for refractory chronic and subacute cutaneous lupus erythematosus: 16 patients
Fennira, F., Chasset, F., Soubrier, M., Cordel, N., Petit, A., & Francès, C. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.01.054 · Cited by 31
Dapsone Suppresses Disease in Preclinical Murine Models of Pemphigoid Diseases
Murthy, S., Schilf, P., Patzelt, S., Thieme, M., Becker, M., Kröger, L., Bremer, T., Derenda-Hell, A., Knebel, L., Fagiani, F., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.04.009 · Cited by 31
Grando, S. A. (2018) · International Journal of Dermatology · doi:10.1111/ijd.14143 · Cited by 30
A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach
Jarrett, P., & Werth, V. P. (2019) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s179623 · Cited by 30
Prevalence of Prurigo Nodularis in Poland
Ryczek, A., & Reich, A. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3518 · Cited by 30 · cited 1×
“Epidemiological studies are infrequent and report different prevalences depending on the method and population included (13, 91, 92).”
BackgroundIdentification of novel therapeutic targets for blocking acantholysis in pemphigus
Burmester, I. A. K., Flaswinkel, S., Thies, C., Kasprick, A., Kamaguchi, M., Bumiller‐Bini, V., Emtenani, S., Feldmann, N., Kridin, K., Schmidt, E., et al. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15233 · Cited by 29
Therapeutic potential of biologics in prurigo nodularis
Müller, S., Bieber, T. R. M., & Ständer, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1958777 · Cited by 29 · cited 1×
“Currently, opioid modulators and investigational substances (dupilumab, nemolizumab) are recommended as off-label treatments in refractory cases (104, 105).”
BackgroundEthnic differences in the epidemiology of cutaneous lupus erythematosus in New Zealand
Jarrett, P., Thornley, S., & Scragg, R. K. R. (2016) · Lupus · doi:10.1177/0961203316651745 · Cited by 28
Tocilizumab treatment in patients with Schnitzler syndrome: An open-label study
Bonnekoh, H., Frischbutter, S., Roll, S., Maurer, M., & Krause, K. (2021) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2021.01.024 · Cited by 28
Chronic Prurigo: Similar Clinical Profile and Burden Across Clinical Phenotypes
Zeidler, C., Pereira, M. P., & Ständer, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.649332 · Cited by 28 · cited 1×
“Prurigo Nodularis Prurigo nodularis (PN) belongs to the spectrum of chronic prurigo and it is the dominant phenotype for 70% of patients with chronic prurigo (13, 88, 89).”
BackgroundTarazi, M., Gaffney, R. G., Kushner, C. J., Chakka, S., & Werth, V. P. (2019) · Arthritis Care & Research · doi:10.1002/acr.23916 · Cited by 27
Impact of tofacitinib on patient outcomes in rheumatoid arthritis – review of clinical studies
Boyce, E. G., Vyas, D., Rogan, E. L., Valle-Oseguera, C. S., & O’Dell, K. M. (2016) · Patient Related Outcome Measures · doi:10.2147/prom.s62879 · Cited by 26
Werth, V. P., Furie, R. A., Romero‐Díaz, J., Navarra, S., KALUNIAN, K. C., van Vollenhoven, R., Nyberg, F., Kaffenberger, B. H., Sheikh, S. Z., Radunović, G., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-eular.5743 · Cited by 25
Medium-dose prednisolone pulse therapy in alopecia areata
Efentaki, P., Altenburg, A., Haerting, J., & Zouboulis, C. C. (2009) · Dermato-Endocrinology · doi:10.4161/derm.1.6.11236 · Cited by 24
De, D., Bishnoi, A., Handa, S., Mahapatra, T., & Mahajan, R. (2019) · Indian Journal of Dermatology Venereology and Leprology · doi:10.4103/ijdvl.ijdvl_848_17 · Cited by 24
Successful Treatment of Cutaneous Lesions of Dermatomyositis with Topical Pimecrolimus
Kim, J. E., Jeong, M. G., Lee, H. E., Ko, J. Y., & Ro, Y. S. (2011) · Annals of Dermatology · doi:10.5021/ad.2011.23.3.348 · Cited by 23
Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes
Bodar, E. J., Simon, A., & van der Meer, J. W. M. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00039 · Cited by 23
Lamberts, A., Yale, M., Grando, S. A., Horváth, B., Zillikens, D., & Jonkman, M. F. (2018) · Acta Dermato Venereologica · doi:10.2340/00015555-3052 · Cited by 23
Mortality and clinical response of patients with bullous pemphigoid treated with rituximab
Yoo, D. S., Lee, J. H., Kim, S., & Kim, J. H. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19890 · Cited by 23
Li, X., Qian, H., Natsuaki, Y., Koga, H., Kawakami, T., Tateishi, C., Tsuruta, D., Ishii, N., & Hashimoto, T. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20099 · Cited by 23
The role for JAK inhibitors in the treatment of immune-mediated rheumatic and related conditions
Fragoulis, G. E., Brock, J., Basu, N., McInnes, I. B., & Siebert, S. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.08.010 · Cited by 23 · cited 1×
“The background for the latter development is the recognition that many mediators, for example type I interferons or IL-23, mediate their inflammatory signals via Janus kinases (JAK, to which TYK2 also belongs) (85, 86).”
BackgroundGastrointestinal involvement of primary skin diseases
Lu, C., Hsieh, M., Wei, K., Ezmerli, M., Kuo, C., & Chen, W. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16676 · Cited by 22
Riemekasten, G., & Cabral-Marques, O. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.04.004 · Cited by 21
Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review
Betrains, A., Staels, F., & Vanderschueren, S. (2020) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2020.05.002 · Cited by 21
Boch, K., Langan, E. A., Zillikens, D., Ludwig, R. J., & Kridin, K. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.16191 · Cited by 21
The Role of Myositis-Specific Autoantibodies in the Dermatomyositis Spectrum
Ramesh, H. M., Gude, S. S., Venugopal, S., Peddi, N. C., Gude, S. S., & Vuppalapati, S. (2022) · Cureus · doi:10.7759/cureus.22978 · Cited by 21
Autoantibodies Associated with Rheumatic Diseases
Griesmacher, A., & Peichl, P. (2001) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2001.031 · Cited by 19
van Leersum, F. S., Potjewijd, J., van Geel, M., Steijlen, P. M., & Vreeburg, M. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1117-2 · Cited by 19 · cited 1×
“Schnitzler’s syndrome Orphan Higher among males None NA (29, 30)”
BackgroundEpidemiology of hidradenitis suppurativa in Taiwan: A 14‐year nationwide population‐based study
Liang, Y., Yeh, C., Huang, J., & Wei, J. C. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15811 · Cited by 19
Prevalence and presumptive triggers of localized bullous pemphigoid
Ständer, S., Kasperkiewicz, M., Thaçi, D., Schmidt, E., Zillikens, D., Vorobyev, A., & Ludwig, R. J. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15912 · Cited by 19
Expert Perspective: An Evidence‐Based Approach to Refractory Cutaneous Lupus Erythematosus
Borucki, R., & Werth, V. P. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41480 · Cited by 18
Bixio, R., Rossini, M., & Giollo, A. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05501-w · Cited by 18
Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of Disease
Fabbrocini, G., Ruina, G., Giovanardi, G., Dini, V., Raone, B., Venturini, M., Caro, R. D. C., Veraldi, S., Cannavò, S. P., Merlo, G., et al. (2021) · Dermatology · doi:10.1159/000517412 · Cited by 18
Pavlov-Dolijanovic, S. R., DAMJANOV, N. S., Stupar, N. Z. V., Baltić, S., & Babic, D. D. (2013) · Rheumatology International · doi:10.1007/s00296-013-2844-7 · Cited by 17
Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?
Metz, M., & Maurer, M. (2021) · Allergologie select · doi:10.5414/alx02204e · Cited by 17
Landeck, L., Sabat, R., Ghoreschi, K., Man, X., Fuhrmeister, K., Gonzalez-Martinez, E., & Asadullah, K. (2021) · Immunotherapy · doi:10.2217/imt-2020-0292 · Cited by 17
Zillikens, H., Kasprick, A., Osterloh, C., Groß, N., Radziewitz, M., Hass, C., Hartmann, V., Behnen-Härer, M., Ernst, N., Boch, K., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.713312 · Cited by 17
Dupilumab for treatment‐refractory prurigo nodularis
Kovács, B., Rose, E., Kuznik, N., Shimanovich, I., Zillikens, D., Ludwig, R. J., & Thaçi, D. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14107 · Cited by 16 · cited 1×
“Currently, opioid modulators and investigational substances (dupilumab, nemolizumab) are recommended as off-label treatments in refractory cases (104, 105).”
BackgroundStüssel, P., Dieckhoff, K. S., Künzel, S., Hartmann, V., Gupta, Y., Kaiser, G., Veldkamp, W. R., Vidarsson, G., Visser, R., Ghorbanalipoor, S., et al. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.04.025 · Cited by 15
Forming diagnostic criteria for vulvar lichen planus
Wu, M., Lee, G., & Fischer, G. O. (2020) · Australasian Journal of Dermatology · doi:10.1111/ajd.13350 · Cited by 15 · cited 1×
“However, diagnosis is often delayed because of the highly variable clinical appearance and inconsistent histopathological findings in LP (114).”
BackgroundRashid, H., Lamberts, A., van Maanen, D., Bolling, M. C., Diercks, G. F. H., Pas, H. H., Jonkman, M. F., & Horváth, B. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.06.024 · Cited by 14
Kasperkiewicz, M., Lai, O., Kim, G. H., DeClerck, B. K., Woodley, D. T., Zillikens, D., & Recke, A. (2020) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000001817 · Cited by 14
A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab
Fujita, Y., Asano, T., Sakai, A., Norikawa, N., Yamamoto, T., Matsumoto, H., Sato, S., Temmoku, J., Yashiro‐Furuya, M., Matsuoka, N., et al. (2021) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-021-04120-z · Cited by 14
Kridin, K., Kridin, M., Amber, K. T., Shalom, G., Comaneshter, D. S., Batat, E., & Cohen, A. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01559 · Cited by 12
Vitiligo: to biopsy or not to biopsy?
Weiss, M. E. M. (2020) · PubMed · Cited by 12
Drug Development in Pemphigoid Diseases
Bieber, K., & Ludwig, R. J. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3400 · Cited by 11
Promising and Upcoming Treatments in Myositis
Smith, L. N., & Paik, J. J. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00943-2 · Cited by 11
Petruzzi, M., Lucchese, A., Contaldo, M., Tampoia, M., Frassanito, M. A., Lauritano, D., & della Vella, F. (2021) · Oral Diseases · doi:10.1111/odi.13849 · Cited by 11
Overview of Alopecia: A Dermatopathologist's Perspective.
Vidal, C. I. (2015) · PubMed · Cited by 10
Poli, M. C. (2018) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000696 · Cited by 10
Gasparini, G., Cozzani, E., Zenzo, G. D., Salemme, A., Dematté, E., Vassallo, C., Marzano, A. V., Genovese, G., Caproni, M., Antiga, E., et al. (2022) · European Journal of Dermatology · doi:10.1684/ejd.2021.4104 · Cited by 10
Larsen, C. K., Andersen, R. K., Kirby, J. S., Tan, J. K. L., Saunte, D. M. L., & Jemec, G. B. E. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17148 · Cited by 9
Werth, V. P., Merrill, J. T., Furie, R. A., Dörner, T., van Vollenhoven, R., Lipsky, P. E., Weiswasser, M., Korish, S., Schafer, P. H., Stern, M., et al. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-eular.2181 · Cited by 9
Update on Biologics for Psoriasis in Clinical Practice
Ivanic, M. G. (2021) · Cutis · doi:10.12788/cutis.0317 · Cited by 9
Prevalence of Pemphigoid as a Potentially Unrecognized Cause of Pruritus in Nursing Home Residents
Meijer, J. M., Lamberts, A., Luijendijk, H. J., Diercks, G. F. H., Pas, H. H., Zuidema, S. U., & Jonkman, M. F. (2019) · JAMA Dermatology · doi:10.1001/jamadermatol.2019.3308 · Cited by 8 · cited 2×
“By contrast, atypical clinical presentations, which occur in least 20% of all BP patients, diagnosis is often delayed by several months, if not years (4, 218, 219).”
BackgroundGupta, M. A., Vujčić, B., Sheridan, A. D., & Gupta, A. K. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16224 · Cited by 8
Ujiie, I., Iwata, H., Yoshimoto, N., Izumi, K., Shimizu, H., & Ujiie, H. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15816 · Cited by 8
Rubio, J., & Kyttaris, V. C. (2021) · ACR Open Rheumatology · doi:10.1002/acr2.11338 · Cited by 7
Reliability and validity of the Vitiligo Signs of Activity Score
Eleftheriadou, V. (2020) · British Journal of Dermatology · doi:10.1111/bjd.19164 · Cited by 6
Resolution of Schnitzler's syndrome after haematopoietic stem cell transplantation
Paladini, A., Vitale, A., Frediani, B., & Cantarini, L. (2021) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/1r3i7i · Cited by 6
Bullous pemphigoid: Rituximab to the rescue?
Heymann, W. R. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.02.058 · Cited by 5
18F-florbetaben positron emission tomography detects cardiac involvement in systemic AA amyloidosis
Παπαθανασίου, Μ., Carpinteiro, A., Hagenacker, T., Herrmann, K., Rassaf, T., Rischpler, C., & Luedike, P. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04861-4 · Cited by 4
Rituximab versus Mycophenolate Mofetil in Pemphigus Vulgaris
Hopkins, Z. H., Wu, B. C., & Nousari, C. H. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2111763 · Cited by 4
Delayed effort-induced swelling with myofasciitis and systemic manifestations
Bursztejn, A. ‐., & Lipsker, D. M. (2017) · Medicine · doi:10.1097/md.0000000000006112 · Cited by 2
Flagged first, then by citations
2 of the 389 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Bieber, K., Hundt, J. E., Yu, X., Ehlers, M., Petersen, F., Karsten, C. M., Köhl, J., Kridin, K., Kalies, K., Kasprick, A., et al. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103236 · Cited by 135
Comprehensive Insight into Lichen Planus Immunopathogenesis
Vičić, M., Hlača, N., Kaštelan, M., Brajac, I., Tokmadžić, V. S., & Massari, L. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24033038 · Cited by 123
“Skin LP is generally followed by severe pruritus, whose intensity corresponds to the affected surface but lacks visible scratches or secondary infections [5].”
BackgroundInfluentialHidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape
Krueger, J. G., Frew, J. W., Jemec, G. B. E., Kimball, A. B., Kirby, B., Bechara, F. G., Navrazhina, K., Prens, E. P., Reich, K., Cullen, E., et al. (2023) · British Journal of Dermatology · doi:10.1093/bjd/ljad345 · Cited by 115
Systematic Review of Deep Learning Image Analyses for the Diagnosis and Monitoring of Skin Disease
Choy, S. P., Kim, B. J., Paolino, A., Tan, W. R., Lim, S. M. L., Seo, J., Tan, S. P., Francis, L., Tsakok, T., Simpson, M., et al. (2023) · npj Digital Medicine · doi:10.1038/s41746-023-00914-8 · Cited by 105
Therapeutic strategies for oral lichen planus: State of the art and new insights
Didona, D., Caro, R. D. C., Santos, A. M. S., Solimani, F., & Hertl, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.997190 · Cited by 101
“89% and it is more commonly diagnosed in the female population (1, 2).”
Background
Metadata
- Authors
- Ujiie, H., Rosmarin, D., Schön, M. P., Ständer, S., Boch, K., Metz, M., Maurer, M., Thaci, D., Schmidt, E., Cole, C., Amber, K. T., Didona, D., Hertl, M., Recke, A., Graßhoff, H., Hackel, A., Schumann, A., Riemekasten, G., Bieber, K., Sprow, G., Dan, J., Zillikens, D., Sezin, T., Christiano, A. M., Wolk, K., Sabat, R., Kridin, K., Werth, V. P., & Ludwig, R. J.
- Affiliations
- Hokkaido University (JP)
- Tufts Medical Center (US)
- Universitätsmedizin Göttingen (DE)
- University Hospital Münster (DE)
- University of Lübeck (DE)
- Humboldt-Universität zu Berlin (DE)
- Rush University Medical Center (US)
- Philipps University of Marburg (DE)
- Philadelphia VA Medical Center (US)
- Columbia University Irving Medical Center (US)
- Charité – Universitätsmedizin Berlin (DE)
- Bar-Ilan University (IL)
- Corresponding author
- Ludwig, Ralf J.
- ORCID
- Ujiie, Hideyuki
- Rosmarin, David
- Schön, Michael P.
- Ständer, Sonja
- Boch, Katharina
- Metz, Martin
- Maurer, Marcus
- Schmidt, Enno
- Cole, Connor
- Amber, Kyle T.
- Didona, Dario
- Hertl, Michael
- Recke, Andreas
- Graßhoff, Hanna
- Hackel, Alexander
- Riemekasten, Gabriela
- Bieber, Katja
- Dan, Joshua
- Zillikens, Detlef
- Sezin, Tanya
- Christiano, Angela M.
- Wolk, Kerstin
- Sabat, Robert
- Kridin, Khalaf
- Werth, Victoria P.
- Ludwig, Ralf J.
- Venue
- Frontiers in Medicine
- Publisher
- Frontiers Media SA
- Published
- 2022-06-09
- Volume
- 9
- Pages
- 875492-875492
- ISSN
- 2296-858X (ISSN-L)
- PMC
- PMC9218547
- OpenAlex
- W4285740668
- Cited by
- 158
- References
- 389
- Citations by year
- 2026: 20 · 2025: 40 · 2024: 49 · 2023: 37 · 2022: 12
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Fraunhofer-Publica (Fraunhofer-Gesellschaft) (submittedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (EXC 2167, FOR 2497, FOR 2690, RI/1056-11,, SFB 1526)
- National Institutes of Health (R01AR071653, R01AR076766)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (CRSII5_202301/1)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Keywords
- chronic inflammatory skin disease, unmet medical needs, atopic dermatitis, psoriasis, urticaria, lichen planus, hidradenitis suppurativa, alopecia areata, vitiligo, pemphigus, pemphigoid diseases, cutaneous lupus erythematosus, dermatomyositis, autoinflammatory disease, systemic immunosuppression, biomarkers, treatment response prediction, early diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
